American Society for Preventive Cardiology

Seven barriers to prescribing PCSK9 inhibitorsThe National Lipid Association releases interesting survey results on PCSK9 inhibitors prescription approval process.
Game-changing cholesterol-buster further reduces heart attack, strokeA new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%.